Sparrow Pharmaceuticals to Present on HSD-1 Inhibitor Clofutriben (SPI-62) for Polymyalgia Rheumatica at the European Congress of Rheumatology 2024
- Presentation will describe how clofutriben modulates key biomarkers of prednisolone efficacy and toxicity in patients with polymyalgia rheumatica.
- Sparrow’s Chief Scientific Officer will describe new insights about glucocorticoid action on the 75th anniversary of glucocorticoid utilization for treatment of rheumatic diseases.
PORTLAND, Ore.–(BUSINESS WIRE)–
Sparrow’s Founder and Chief Scientific Officer will describe how clofutriben modulates key biomarkers of prednisolone efficacy and toxicity in his presentation, “The 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 Differentially Modulates Prednisolone Immune and Musculoskeletal Efficacy and Bone Formation/Resorption Biomarkers in Patients with Polymyalgia Rheumatica (PMR): An Interim Report.”
Presenter: Dr. David Katz, Ph.D., Chief Scientific Officer, Sparrow Pharmaceuticals
Session Location: Room C7
Session Time: 15 June 2024 at 12:50 CEDT
To learn more about Sparrow Pharmaceuticals clofutriben, visit www.sparrowpharma.com.
About Sparrow Pharmaceuticals
Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into glucocorticoid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, clofutriben (SPI-62), is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular glucocorticoids in key tissues.
Contacts
Alexis Feinberg
ICR Westwicke
[email protected]
203-939-2225
